DK1567522T3 - Pyrimidinforbindelser - Google Patents

Pyrimidinforbindelser

Info

Publication number
DK1567522T3
DK1567522T3 DK03811029T DK03811029T DK1567522T3 DK 1567522 T3 DK1567522 T3 DK 1567522T3 DK 03811029 T DK03811029 T DK 03811029T DK 03811029 T DK03811029 T DK 03811029T DK 1567522 T3 DK1567522 T3 DK 1567522T3
Authority
DK
Denmark
Prior art keywords
pyrimidine
disorders
cdks
cyclin
inhibitors
Prior art date
Application number
DK03811029T
Other languages
Danish (da)
English (en)
Inventor
Shudong Wang
Christopher Meades
Janice O'boyle
Campbell Mcinnes
Peter Fischer
Gavin Wood
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Application granted granted Critical
Publication of DK1567522T3 publication Critical patent/DK1567522T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK03811029T 2002-11-14 2003-11-14 Pyrimidinforbindelser DK1567522T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0226583.3A GB0226583D0 (en) 2002-11-14 2002-11-14 Compounds
PCT/GB2003/004973 WO2004043953A1 (en) 2002-11-14 2003-11-14 Pyrimidine compounds

Publications (1)

Publication Number Publication Date
DK1567522T3 true DK1567522T3 (da) 2007-11-05

Family

ID=9947823

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03811029T DK1567522T3 (da) 2002-11-14 2003-11-14 Pyrimidinforbindelser

Country Status (17)

Country Link
US (2) US7432260B2 (de)
EP (2) EP1864983A1 (de)
JP (1) JP4681880B2 (de)
CN (1) CN100415740C (de)
AT (1) ATE373653T1 (de)
AU (1) AU2003301977A1 (de)
BR (1) BR0316152A (de)
CA (1) CA2502190A1 (de)
CY (1) CY1106933T1 (de)
DE (1) DE60316468T2 (de)
DK (1) DK1567522T3 (de)
ES (1) ES2293094T3 (de)
GB (1) GB0226583D0 (de)
MX (1) MXPA05005199A (de)
NZ (1) NZ539670A (de)
PT (1) PT1567522E (de)
WO (1) WO2004043953A1 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
CN1678321A (zh) 2002-07-29 2005-10-05 里格尔药品股份有限公司 用2,4－嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
GB0229581D0 (en) * 2002-12-19 2003-01-22 Cyclacel Ltd Use
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
EP1656372B1 (de) 2003-07-30 2013-04-10 Rigel Pharmaceuticals, Inc. 2,4-pyrimidindiamine derivate zur behandlung oder vorbeugung von autoimmunerkrankungen
EP1678171B1 (de) * 2003-10-21 2016-09-14 Cyclacel Limited 2-amino-4-thiazolon-pyrimidinderivate als proteinkinaseinhibitoren
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
GB0402653D0 (en) * 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
WO2005113550A1 (ja) * 2004-05-20 2005-12-01 Mitsubishi Pharma Corporation アミノピリミジン誘導体及びその医薬としての用途
GB0411791D0 (en) * 2004-05-26 2004-06-30 Cyclacel Ltd Compounds
PL1799230T3 (pl) 2004-08-27 2013-05-31 Cyclacel Ltd Purynowe i pirymidynowe inhibitory CDK i ich zastosowanie do leczenia chorób autoimmunologicznych
GT200500286A (es) * 2004-10-13 2006-06-13 Analogos de anilino-pirimidina
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
BRPI0517253A (pt) * 2004-10-28 2008-10-07 Irm Llc compostos e composições como moduladores de trajetória de ouriço
JP4932735B2 (ja) * 2004-12-17 2012-05-16 アムジエン・インコーポレーテツド アミノピリミジン化合物および使用方法
WO2006076442A2 (en) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
SG137989A1 (en) 2005-06-08 2008-01-28 Rigel Pharmaceuticals Inc Compositions and methods for inhibition of the JAK pathway
EP2258358A3 (de) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
AR058073A1 (es) * 2005-10-03 2008-01-23 Astrazeneca Ab Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB0520955D0 (en) * 2005-10-14 2005-11-23 Cyclacel Ltd Compound
GB0520958D0 (en) * 2005-10-14 2005-11-23 Cyclacel Ltd Compound
EP1940389A2 (de) 2005-10-21 2008-07-09 Braincells, Inc. Modulation von neurogenese durch pde-hemmung
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
AU2006315436A1 (en) * 2005-11-15 2007-05-24 Vertex Pharmaceuticals Incorporated Azaindazoles useful as inhibitors of kinases
WO2007084391A2 (en) * 2006-01-18 2007-07-26 Amgen Inc. Thiazole compounds as protein kinase b ( pkb) inhibitors
CA2642229C (en) 2006-02-24 2015-05-12 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007132220A1 (en) * 2006-05-12 2007-11-22 Cyclacel Limited Combination of a 2-substituted-4-heter0aryl-pyrimidine amine with a cytotoxic drug and use thereof in the treatment of a proliferative disorder
WO2007132221A1 (en) * 2006-05-12 2007-11-22 Cyclacel Limited Combined anticancer pyrimidine-thiazole aurora kinase inhibitors
GB0609530D0 (en) * 2006-05-12 2006-06-21 Cyclacel Ltd Combination
EP2064322B1 (de) * 2006-06-14 2012-04-25 Vertex Pharmceuticals Incorporated Kristallstruktur der polo-like-kinase 3 (plk3) und bindungstaschen dafür
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EA200970361A1 (ru) 2006-10-09 2010-02-26 Такеда Фармасьютикал Компани Лимитед Ингибиторы киназы
EP2173728A2 (de) 2007-07-17 2010-04-14 Amgen Inc. Heterocyclische pkb-modulatoren
AU2008276512A1 (en) * 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of PKB
JP5501234B2 (ja) * 2007-09-28 2014-05-21 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 置換ピロロ−ピリミジン誘導体、これらの調製方法およびキナーゼ阻害剤としてのこれらの使用
WO2009103032A1 (en) 2008-02-15 2009-08-20 Rigel Pharmaceuticals, Inc. Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases
GB0805477D0 (en) * 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
MX2011006725A (es) 2008-12-22 2011-09-15 Millennium Pharm Inc Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20.
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CA2761064A1 (en) 2009-04-15 2010-10-21 Astrazeneca Ab Imidazole substituted pyrimidines useful in the treatment of glycogen synthase kinase 3 related disorders such as alzheimer's disease
HU0900798D0 (en) * 2009-12-21 2010-03-01 Vichem Chemie Kutato Kft 4-phenylamino-pyrimidine derivatives having protein kinase inhibitor activity
JP6525474B2 (ja) 2013-12-06 2019-06-05 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼ阻害剤と抗ｃｄ３０抗体の併用
CN105267214B (zh) * 2014-07-21 2019-04-30 沈阳化工研究院有限公司 N-杂芳基苯胺类化合物作为制备抗肿瘤药物的应用
JP6722178B2 (ja) 2014-10-08 2020-07-15 レデックス ファーマ ピーエルシーＲｅｄｘ Ｐｈａｒｍａ Ｐｌｃ Ｗｎｔシグナル伝達経路の阻害剤としてのｎ−ピリジニルアセトアミド誘導体
EP4071150A1 (de) 2014-10-08 2022-10-12 Redx Pharma Plc N-pyridinylacetamidderivate als inhibitoren des wnt-signaltransduktionsweges
WO2017015316A1 (en) 2015-07-21 2017-01-26 Millennium Pharmaceuticals, Inc. Administration of aurora kinase inhibitor and chemotherapeutic agents
CN108349964B (zh) * 2015-08-04 2021-06-01 常州千红生化制药股份有限公司 N-(吡啶-2-基)-4-(噻唑-5-基)嘧啶-2-胺类化合物作为治疗性化合物
US10696642B2 (en) 2015-09-23 2020-06-30 The General Hospital Corporation TEAD transcription factor autopalmitoylation inhibitors
US20170283445A1 (en) 2016-04-05 2017-10-05 University Of South Carolina Small Molecule Inhibitors Selective For Polo-Like Kinase Proteins
CN109985241B (zh) * 2017-12-29 2024-10-18 广州威溶特医药科技有限公司 Cdk抑制剂和溶瘤病毒在制备抗肿瘤药物的应用
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
US11162083B2 (en) 2018-06-14 2021-11-02 University Of South Carolina Peptide based inhibitors of Raf kinase protein dimerization and kinase activity
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254879B1 (en) * 1991-09-27 2001-07-03 Max-Planck-Gessellschaft zun Förderung der Wissenschaften e.V. Methods of treating protozoal diseases
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
DE60024480T2 (de) * 1999-10-27 2006-07-27 Novartis Ag Thiazol und imidazo[4,5-b]pyridin verbindungen und ihre verwendung als pharmazeutika
HUP0300382A3 (en) 2000-03-29 2006-11-28 Cyclacel Ltd 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders and pharmaceutical compositions containing the compounds
GB0021726D0 (en) * 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
JP4160395B2 (ja) * 2000-12-21 2008-10-01 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用なピラゾール化合物
SE0100569D0 (sv) * 2001-02-20 2001-02-20 Astrazeneca Ab New compounds
GB0107901D0 (en) 2001-03-29 2001-05-23 Cyclacel Ltd Anti-cancer compounds
IL161092A0 (en) * 2001-09-28 2004-08-31 Cyclacel Ltd N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-n-phenylamines as antiproliferative compounds
WO2003029048A2 (en) * 2001-10-03 2003-04-10 Snyder Douglas D Pilot authentication using voice biometric
GB0226582D0 (en) 2002-11-14 2002-12-18 Cyclacel Ltd Anti-viral compounds
GB0226583D0 (en) 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
GB0229581D0 (en) 2002-12-19 2003-01-22 Cyclacel Ltd Use
GB0315966D0 (en) 2003-07-08 2003-08-13 Cyclacel Ltd Compounds
AU2004261484A1 (en) 2003-07-30 2005-02-10 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
EP1648887A1 (de) 2003-07-30 2006-04-26 Cyclacel Limited Pyridinylamin-pyrimidin derivate als protein kinase hemmer
EP1678171B1 (de) 2003-10-21 2016-09-14 Cyclacel Limited 2-amino-4-thiazolon-pyrimidinderivate als proteinkinaseinhibitoren
GB0328180D0 (en) 2003-12-04 2004-01-07 Cyclacel Ltd Combination
PL1799230T3 (pl) 2004-08-27 2013-05-31 Cyclacel Ltd Purynowe i pirymidynowe inhibitory CDK i ich zastosowanie do leczenia chorób autoimmunologicznych

Also Published As

Publication number Publication date
CY1106933T1 (el) 2012-09-26
US7432260B2 (en) 2008-10-07
EP1567522B1 (de) 2007-09-19
MXPA05005199A (es) 2005-08-18
ES2293094T3 (es) 2008-03-16
US20050192300A1 (en) 2005-09-01
BR0316152A (pt) 2005-09-27
PT1567522E (pt) 2007-10-09
EP1864983A1 (de) 2007-12-12
CA2502190A1 (en) 2004-05-27
US20080287439A1 (en) 2008-11-20
DE60316468T2 (de) 2008-06-26
NZ539670A (en) 2007-11-30
CN100415740C (zh) 2008-09-03
CN1711258A (zh) 2005-12-21
GB0226583D0 (en) 2002-12-18
WO2004043953A1 (en) 2004-05-27
AU2003301977A1 (en) 2004-06-03
JP4681880B2 (ja) 2011-05-11
US7897605B2 (en) 2011-03-01
DE60316468D1 (de) 2007-10-31
EP1567522A1 (de) 2005-08-31
JP2006514619A (ja) 2006-05-11
ATE373653T1 (de) 2007-10-15

Similar Documents

Publication Publication Date Title
DK1567522T3 (da) Pyrimidinforbindelser
WO2005116025A3 (en) 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders
MXPA04002914A (es) N- (4- (4-metiltiazol-5-il)pirimidin-2-il) -n-fenilaminas como compuestos antiproliferativos.
MY140291A (en) Sulfoximine-substituted pyrimidines for use as cd and/or vegf inhibitors, the production thereof and their use as drugs
ZA200609637B (en) 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors
BRPI0509369A (pt) azaindóis úteis como inibidores de jak e outras proteìna cinases
BRPI0314001B8 (pt) pirazolopirimidinas como inibidores de cinase dependente de ciclina e composição farmacêutica compreendendo as mesmas
MXPA05005223A (es) Diaminotriazoles utiles como inhibidores de proteinas cinasas.
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
DK1347971T3 (da) Thiazolylinhibitorer af tyrosinkinaser fra Tec-familien
MEP13408A (en) Cdk inhibiting pyrimidines, production thereof and their use as medicaments
ATE420883T1 (de) Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
GB2375534B (en) Anti-cancer compounds
NO20082508L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
ZA200710379B (en) Pyrrolopyridines useful as inhibitors of protein kinase
DE602004024374D1 (de) Zusammensetzungen zur verwendung als protein-kinase-inhibitoren
DK1791830T3 (da) Diaminotriazol-forbindelser der er nyttige som protein-kinase-inhibitorer